Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Complete Dosing Guide
What to Monitor
Weight and Body Measurements:
- Weekly weight checks
- Waist circumference monthly
- BMI calculations
Glycemic Control (if diabetic):
- Blood glucose levels
- HbA1c every 3 months
- Continuous glucose monitoring if available
Gastrointestinal Function:
- Nausea severity and frequency
- Bowel movement patterns
- Hydration status
Laboratory Tests:
- Lipid profile
- Liver function tests
- Pancreatic enzymes if symptoms suggest pancreatitis
What to Monitor
Weight and Body Measurements:
- Weekly weight checks
- Waist circumference monthly
- BMI calculations
Glycemic Control (if diabetic):
- Blood glucose levels
- HbA1c every 3 months
- Continuous glucose monitoring if available
Gastrointestinal Function:
- Nausea severity and frequency
- Bowel movement patterns
- Hydration status
Laboratory Tests:
- Lipid profile
- Liver function tests
- Pancreatic enzymes if symptoms suggest pancreatitis
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.